151 related articles for article (PubMed ID: 24949260)
1. Assessment of packed bed bioreactor systems in the production of viral vaccines.
Rajendran R; Lingala R; Vuppu SK; Bandi BO; Manickam E; Macherla SR; Dubois S; Havelange N; Maithal K
AMB Express; 2014; 4():25. PubMed ID: 24949260
[TBL] [Abstract][Full Text] [Related]
2. Benchmarking of Scale-X Bioreactor System in Lentiviral and Adenoviral Vector Production.
Leinonen HM; Lepola S; Lipponen EM; Heikura T; Koponen T; Parker N; Ylä-Herttuala S; Lesch HP
Hum Gene Ther; 2020 Mar; 31(5-6):376-384. PubMed ID: 32075423
[TBL] [Abstract][Full Text] [Related]
3. Process Development of Adenoviral Vector Production in Fixed Bed Bioreactor: From Bench to Commercial Scale.
Lesch HP; Heikkilä KM; Lipponen EM; Valonen P; Müller A; Räsänen E; Tuunanen T; Hassinen MM; Parker N; Karhinen M; Shaw R; Ylä-Herttuala S
Hum Gene Ther; 2015 Aug; 26(8):560-71. PubMed ID: 26176404
[TBL] [Abstract][Full Text] [Related]
4. Pseudorabies virus production using a serum-free medium in fixed-bed bioreactors with low cell inoculum density.
Nie J; Sun Y; Peng F; Han F; Yang Y; Liu X; Liu C; Li Y; Bai Z
Biotechnol Lett; 2020 Dec; 42(12):2551-2560. PubMed ID: 32816175
[TBL] [Abstract][Full Text] [Related]
5. Development and Optimization of AAV hFIX Particles by Transient Transfection in an iCELLis(®) Fixed-Bed Bioreactor.
Powers AD; Piras BA; Clark RK; Lockey TD; Meagher MM
Hum Gene Ther Methods; 2016 Jun; 27(3):112-21. PubMed ID: 27229773
[TBL] [Abstract][Full Text] [Related]
6. Lentiviral Vector Production from a Stable Packaging Cell Line Using a Packed Bed Bioreactor.
Powers AD; Drury JE; Hoehamer CF; Lockey TD; Meagher MM
Mol Ther Methods Clin Dev; 2020 Dec; 19():1-13. PubMed ID: 32995355
[TBL] [Abstract][Full Text] [Related]
7. Optimization of lentiviral vector production for scale-up in fixed-bed bioreactor.
Valkama AJ; Leinonen HM; Lipponen EM; Turkki V; Malinen J; Heikura T; Ylä-Herttuala S; Lesch HP
Gene Ther; 2018 Jan; 25(1):39-46. PubMed ID: 29345252
[TBL] [Abstract][Full Text] [Related]
8. Production of Recombinant Rabies Virus Glycoprotein by Insect Cells in a Single-Use Fixed-Bed Bioreactor.
Ventini-Monteiro DC; Astray RM; Pereira CA
Methods Mol Biol; 2018; 1674():87-94. PubMed ID: 28921430
[TBL] [Abstract][Full Text] [Related]
9. Production Process Development of Pseudorabies Virus Vaccine by Using a Novel Scale-Down Model of a Fixed-Bed Bioreactor.
Nie J; Sun Y; Peng F; Li X; Yang Y; Liu X; Li Y; Liu C; Bai Z
J Pharm Sci; 2020 Feb; 109(2):959-965. PubMed ID: 31604085
[TBL] [Abstract][Full Text] [Related]
10. Insect cell entrapment, growth and recovering using a single-use fixed-bed bioreactor. Scaling up and recombinant protein production.
Ventini-Monteiro D; Dubois S; Astray RM; Castillo J; Pereira CA
J Biotechnol; 2015 Dec; 216():110-5. PubMed ID: 26481831
[TBL] [Abstract][Full Text] [Related]
11. Development of a high-yield live-virus vaccine production platform using a novel fixed-bed bioreactor.
Berrie DM; Waters RC; Montoya C; Chatel A; Vela EM
Vaccine; 2020 Apr; 38(20):3639-3645. PubMed ID: 32247568
[TBL] [Abstract][Full Text] [Related]
12. Production of influenza H1N1 vaccine from MDCK cells using a novel disposable packed-bed bioreactor.
Sun B; Yu X; Kong W; Sun S; Yang P; Zhu C; Zhang H; Wu Y; Chen Y; Shi Y; Zhang X; Jiang C
Appl Microbiol Biotechnol; 2013 Feb; 97(3):1063-70. PubMed ID: 22945265
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the Single-Use Fixed-Bed Bioreactors in Scalable Virus Production.
Lesch HP; Valonen P; Karhinen M
Biotechnol J; 2021 Jan; 16(1):e2000020. PubMed ID: 32971565
[TBL] [Abstract][Full Text] [Related]
14. Adaptation of Vero cells to suspension growth for rabies virus production in different serum free media.
Rourou S; Ben Zakkour M; Kallel H
Vaccine; 2019 Nov; 37(47):6987-6995. PubMed ID: 31201054
[TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2 Production in a Scalable High Cell Density Bioreactor.
Offersgaard A; Duarte Hernandez CR; Pihl AF; Costa R; Venkatesan NP; Lin X; Van Pham L; Feng S; Fahnøe U; Scheel TKH; Ramirez S; Reichl U; Bukh J; Genzel Y; Gottwein JM
Vaccines (Basel); 2021 Jun; 9(7):. PubMed ID: 34209694
[TBL] [Abstract][Full Text] [Related]
16. A microcarrier cell culture process for propagating rabies virus in Vero cells grown in a stirred bioreactor under fully animal component free conditions.
Rourou S; van der Ark A; van der Velden T; Kallel H
Vaccine; 2007 May; 25(19):3879-89. PubMed ID: 17307281
[TBL] [Abstract][Full Text] [Related]
17. Optimizing and developing a scalable, chemically defined, animal component-free lentiviral vector production process in a fixed-bed bioreactor.
Fiol CR; Collignon ML; Welsh J; Rafiq QA
Mol Ther Methods Clin Dev; 2023 Sep; 30():221-234. PubMed ID: 37528866
[TBL] [Abstract][Full Text] [Related]
18. Bioreactor production of rVSV-based vectors in Vero cell suspension cultures.
Kiesslich S; Kim GN; Shen CF; Kang CY; Kamen AA
Biotechnol Bioeng; 2021 Jul; 118(7):2649-2659. PubMed ID: 33837958
[TBL] [Abstract][Full Text] [Related]
19. Serum-free microcarrier based production of replication deficient influenza vaccine candidate virus lacking NS1 using Vero cells.
Chen A; Poh SL; Dietzsch C; Roethl E; Yan ML; Ng SK
BMC Biotechnol; 2011 Aug; 11():81. PubMed ID: 21835017
[TBL] [Abstract][Full Text] [Related]
20. Production of rhEPO with a serum-free medium in the packed bed bioreactor.
Deng J; Yang Q; Cheng X; Li L; Zhou J
Chin J Biotechnol; 1997; 13(4):247-52. PubMed ID: 9631260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
